Vogelxo
Upshear-Smith’s testosterone gel, Vogelxo, was granted final approval by the U.S. Food & Drug Administration (FDA) in June 2014, even as the agency continued to investigate a possible link between serious heart problems and the use of testosterone replacement therapy. Thousands of testosterone lawsuits involving such drugs have been filed in U.S. courts on behalf of men who allegedly suffered heart attacks, strokes and other cardiovascular complications due to their use.
Attorneys Reviewing Testosterone Lawsuits
The nationwide law firm of Bernstein Liebhard LLP is now offering free, no-obligation legal reviews to men who may have suffered a heart attack, stroke, deep vein thrombosis, or pulmonary embolism while using prescription low-T therapy. If you or a loved one experienced any of these complications while using Vogelxo, please contact our legal staff at (888) 994-5118 to learn more about filing a Vogelxo lawsuit.
What is Vogelxo?
The FDA approved the sale of Vogelxo in May 2014 to treat adult men who have low or no testosterone due to certain underlying medical conditions. The safety and efficacy of this and other prescription low-T drugs in treating men who are experiencing diminished testosterone levels due to aging has not been proven.
Vogelxo is available in 5g tubes and packets in 1- and 30-count packs; it is also available as a 75g metered-dose pump containing 60 metered 1.25 doses. The testosterone gel is applied at the same time each day to the areas of the shoulders and upper arms that will be covered by a short sleeve t-shirt.
The most common Vogelxo side effects include:
- Skin irritation where the testosterone gel is applied
- Increased red blood cell count
- Headache
- Increased blood pressure
Men who already have an enlarged prostate may experience a worsening of symptoms while using Vogelxo. This and other testosterone treatments may also be linked to an increased risk of prostate cancer.
Other serious side effects that may accompany the use of Vogelxo include:
- Blood clots in the legs or lungs (deep vein thrombosis, pulmonary embolism)
- Possible increased risk of heart attack or stroke
- Lower sperm count when used in In large doses
- Swelling of the ankles, feet, or body, with or without heart failure
- Enlarged or painful breasts.
- Sleep apnea
FDA Testosterone Warnings
- January 2014: Only six months before approving Vogelxo, the FDA announced it was reviewing the safety of all low-T therapies amid concerns that the drugs might increase the risk of heart attacks and strokes in certain men.
- June 2014: The same month it cleared Vogelxo, the FDA ordered new blood clot warnings for al prescription testosterone treatments, including pulmonary embolism and deep vein thrombosis. Read More
- March 2015: Less than a year after approving Vogelxo, the FDA concluded the review announced in January 2015, and ordered low-T manufacturers to add new warnings to their product labels regarding a possible association with heart attacks and strokes. Read More
Legal Help for Those Harmed by Vogelxo
If you or a man you care about suffered a heart attack, stroke or dangerous blood clot while using Vogelxo, now is the time to ensure your legal rights are protected. To learn more about the growing testosterone litigation, please call (888) 994-5118.
- FDA (2015) “Vogelxo Medication Guide” http://www.fda.gov/downloads/Drugs/DrugSafety/UCM448177.pdf
- FDA (2014) “FDA Drug Safety Communication: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products” http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm
- FDA (2014) “FDA adding general warning to testosterone products about potential for venous blood clots” http://www.fda.gov/Drugs/DrugSafety/ucm401746.htm
- FDA (2015) “FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use” http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.
Follow Us
